No Data
TD Cowen Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $59
Needham Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $60
Ionis Pharmaceuticals: Strategic Developments and Robust Pipeline Justify Buy Rating
Ionis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call Transcript Summary
Ionis Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Announced the Pivotal Phase 3 Study Design Following Alignment With the FDA on ION582 for Angelman Syndrome.
Earnings Flash (IONS) IONIS PHARMACEUTICALS Posts Q3 Revenue $134M
No Data
No Data